Two-in-one Approach Could Help Keep Brain Cancer in Check
Gliobastoma is the most common type of brain cancer as well as the most deadly. Most patients live less than two years with this diagnosis. Therefore, new treatments are urgently needed. Researchers in this study feel they have found just that with targeting a specific protein that both halts the division of the cancer cells and stops these cancer cells from spreading into normal tissue. “Current treatments often fail because the tumors spread throughout the brain, and so can’t be fully removed by surgery. If we can target this spread, it may be possible to make therapies more effective. When we target this one protein, we block two key features of the tumor: its ability to divide and its ability to move. It could be a combined therapy in one,” says Parrinello. To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada
6th Homburger Neuroendoscopy Week
Sept. 11-15, 2017; Germany